Thursday, August 01, 2013 6:27:41 PM
ACN: 104 028 042
ASX: LCT
OTCQX: LVCLY
ASX ANNOUNCEMENT
Appendix 4C Quarterly Cash Flow Report 30 June 2013
31July 2013 – Sydney, Australia & Auckland, New Zealand –Living Cell Technologies Limited
today announced its quarterly cash flow report for the quarter ended 30 June 2013. The Appendix 4C
is attached. The company ended the quarter with a cash balance of A$4,504,000 compared to
$4,906,000 last quarter.
Dr Andrea Grant, Managing Director, said “I am pleased to see that LCT’s net cash flow continues to
be well controlled, despite the company supporting two human clinical trial programs. This is
because the costs associated with both clinical programs are being recouped, through the joint
venture Diatranz Otsuka Limited for DIABECELL®
as a treatment for type 1 diabetes; and through the
co-development partnership with Otsuka Pharmaceutical Factory, for NTCELL®
as a treatment for
Parkinson’s disease”.
Net operating cash flow in the quarter was ($398,000) compared to $2,553,000last quarter. Receipts
from customers were $2,178,000 (last quarter $4,808,000). The prime reason for the decrease in
these items is the receipt in the last quarter of the $3,000,000 option fee,less a $150,000 withholding
tax,from Otsuka Pharmaceutical Factory, Inc.
Operating payments were $2,640,000 compared to $2,289,000 last quarter. 83% of these payments
are recovered as receipts from customers through LCT’s co-development and joint venture
agreements as they includecostsfor NTCELL clinical development and the services provided to
Diatranz Otsuka Limited for the development of DIABECELL.
– Ends –
http://www.lctglobal.com/html/blob.php/LCT%20Quarterly%20Report%20Jun%2013.pdf?filetypecode=1&document=5112
http://www.lctglobal.com/
Never buy or sell based on my posts.Always consult with a licensed securities professional before you buy or sell any security.My posts are opinions only.Never use them as due diligence.My positions are subject to change without notice.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM